Pegrizeprument clinical trials
Also written FR104 and VEL-101.
How each study uses pegrizeprument is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pegrizeprument studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Veloxis Pharmaceuticals (2) · Nantes University Hospital (1) · OSE Immunotherapeutics (1)
Studies
Open first, then newest update. How each study uses pegrizeprument is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- VEL-101 to Prevent Rejection After Kidney TransplantationRecruitingPhase 2Veloxis PharmaceuticalsNCT07290777Written as VEL-101
- Phase I/II Study of FR104 First Administration In Patient With Renal Transplantation: FIRsT StudyCompletedPhase 1/2Nantes University HospitalNCT04837092Written as FR104
- A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101CompletedPhase 1Veloxis PharmaceuticalsNCT05238493Written as VEL-101
- Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104CompletedPhase 1OSE ImmunotherapeuticsNCT02800811Written as FR104
Codes
What other systems call pegrizeprument · ClinicalTrials.gg INT016096
- UNII (FDA) BCH73Z4RPXPEGRIZEPRUMENTOne source FDA
- NCI Thesaurus C206965PegrizeprumentOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BCH73Z4RPX | PEGRIZEPRUMENT | One source FDA |
| NCI Thesaurus | C206965 | Pegrizeprument | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.